Analysis of direct medical and nonmedical costs for care of rheumatoid arthritis patients using the large cohort database, IORRA

REFERENCES

• Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, T2T Expert Committee, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69: 631–7.
   Google Scholar
• O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med. 2004;350:2591–602.
   PubMed Web of Science ®Google Scholar
• Bakker MF, Jacobs JW, Verstappen SM, Bijlsma JW. Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis. 2007;66\(Suppl 3):iii56–60.
   Google Scholar
• Tanaka E, Mannalithara A, Inoue E, Hara M, Tomatsu T, Kamatani N, et al. Efficient management of rheumatoid arthritis significantly reduces long-term functional disability. Ann Rheum Dis. 2008;67:1153–8.
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Inoue E, Tanaka E, Nakajima A, Taniguchi A, Terai C, et al. Influence of methotrexate dose on its efficacy and safety in rheumatoid arthritis patients: evidence based on the variety of prescribing approaches among practicing Japanese rheumatologists in a single institute-based large observational cohort (IORRA). Mod Rheumatol. 2007;17:98–105.
   PubMedGoogle Scholar
• Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the man-agement of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010; 69:964–75.
   PubMed Web of Science ®Google Scholar
• Boonen A, Severens JL. The burden of illness of rheumatoid arthritis. Clin Rheumatol. 2011;30(Suppl 1):S3–8.
   Google Scholar
• Fautrel B, Clarke AE, Guillemin F, Adam V, St-Pierre Y, Panaritis T, et al. Costs of rheumatoid arthritis: new estimates from the human capital method and comparison to the willing-ness-to-pay method. Med Decis Mak. 2007;27:138–50.
   Google Scholar
• Jacobsson LT, Lindroth Y, Marsal L, Juran E, Bergstrom U, Kobelt G. Rheumatoid arthritis: what does it cost and what fac-tors are driving those costs? Results of a survey in a community-derived population in Malmo, Sweden. Scand J Rheumatol. 2007; 36:179–83.
   PubMed Web of Science ®Google Scholar
• Fautrel B, Guillemin F. Cost of illness studies in rheumatic dis-eases. Curr Opin Rheumatol. 2002;14:121–6.
   PubMed Web of Science ®Google Scholar
• Pugner KM, Scott DI, Holmes JW, Hieke K. The costs of rheu-matoid arthritis: an international long-term view. Semin Arthritis Rheum. 2000;29:305–20.
   PubMed Web of Science ®Google Scholar
• Yelin E, Murphy L, Cisternas MG, Foreman AJ, Pasta DJ, Hel-mick CG. Medical care expenditures and earnings losses among persons with arthritis and other rheumatic conditions in 2003, and comparisons with 1997. Arthritis Rheum. 2007;56: 1397–407.
   Google Scholar
• Lundqvist J, Kastäng F, Kobelt G, Jonsson B. The burden of rheumatoid arthritis and access to treatment: determinants of access. Eur J Health Econ. 2008;8:587–93.
   Web of Science ®Google Scholar
• Yamanaka H, Tohma S. Potential impact of observational cohort studies in Japan on rheumatoid arthritis research and practice. Mod Rheumatol. 2006;16:75–6.
   PubMedGoogle Scholar
• Matsuda Y, Singh G, Yamanaka H, Tanaka E, Urano W, Tan-iguchi A, et al. Validation of a Japanese version of the Stanford Health Assessment Questionnaire in 3,763 patients with rheu-matoid arthritis. Arthritis Rheum. 2003;49: 784–8.
   Google Scholar
• Yamanaka H, Inoue E, Singh G, Tanaka E, Nakajima A, Tan-iguchi A, et al. Improvement of disease activity of rheumatoid arthritis patients from 2000 to 2006 in a large observational cohort study IORRA in Japan. Mod Rheumatol. 2007;17: 283–9.
   Google Scholar
• Seto Y, Tanaka E, Inoue E, Nakajima A, Taniguchi A, MomoharaS, et al. Studies of the efficacy and safety of methotrexate at dosages over 8 mg/week using the IORRA cohort database. Mod Rheumatol. 2011;21:579–93.
   PubMed Web of Science ®Google Scholar
• Okamoto H, Koizumi K, Kamitsuji S, Inoue E, Hara M, Tomatsu T, et al. Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort. J Rheumatol. 2007;34: 964–8.
   PubMed Web of Science ®Google Scholar
• Yamada T, Nakajima A, Inoue E, Tanaka E, Hara M, Tomatsu T, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan. Ann Rheum Dis. 2006;65:1661–3.
   PubMed Web of Science ®Google Scholar
• Yamada T, Nakajima A, Inoue E, Tanaka E, Taniguchi A, Momohara S, et al. Incidence of malignancy in Japanese patients with rheumatoid arthritis. Rheumatol Int. 2011;31:1487–92.
   PubMed Web of Science ®Google Scholar
• Tanaka E, Saito A, Kamitsuji S, Yamada T, Nakajima A, Tan-iguchi A, et al. Impact of shoulder, elbow, and knee joint involvement on assessment of rheumatoid arthritis using the American College of Rheumatology Core Data Set. Arthritis Rheum. 2005;53:864–71.
   Google Scholar
• Furuya T, Kotake S, Inoue E, Nanke Y, Yago T, Kobashigawa T, et al. Risk factors associated with incident clinical vertebral and nonvertebral fractures in Japanese women with rheumatoid arthritis: a prospective 54-month observational study. J Rheuma-tol. 2007;34:303–10.
   PubMed Web of Science ®Google Scholar
• Momohara S, Inoue E, Ikari K, Yano K, Tokita A, Honjo Y, et al. Comparison of characteristics and therapeutic efficacy in rheu-matoid arthritis patients treated by rheumatologists and those treated by orthopedic surgeons under a team medicine approach at the same institute. Mod Rheumatol. 2012;22(2):209–15.
   PubMed Web of Science ®Google Scholar
• Nakajima A, Inoue E, Tanaka E, Singh G, Sato E, Hoshi D, et al. Mortality and cause of death in Japanese patients with rheuma-toid arthritis based on a large observational cohort, IORRA. Scand J Rheumatol. 2010;39:360–7.
   PubMed Web of Science ®Google Scholar
• Tanaka E, Mannalithara A, Inoue E, Iikuni N, Taniguchi A, Momohara S, et al. Effects of long-term corticosteroid usage on functional disability in patients with early rheumatoid arthritis, regardless of controlled disease activity. Rheumatol Int. 2012; 32:749–57.
   PubMed Web of Science ®Google Scholar
• Tanaka E, Inoue E, Mannalithara A, Bennett M, Kamitsuji S, Taniguchi A, et al. Medical care costs of patients with rheumatoid arthritis during the prebiologics period in Japan: a large pro-spective observational cohort study. Mod Rheumatol. 2010;20: 46–53.
   PubMed Web of Science ®Google Scholar
• The Japanese EuroQol Translation Team. The development of the Japanese EuroQol instrument (in Japanese). J Health Care Soc. 1998;8:109–24.
   Google Scholar
• Rdsänen P, Roine E, Sintonen H, Semberg-Konttinen V, Ryyndnen OP, Roine R. Use of quality-adjusted life years for the estimation of effectiveness of health care: a systematic literature review. Int J Technol Assess Health Care. 2006;22:235–41.
   Google Scholar
• Tosh JC, Longworth LJ, George E. Utility values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals. Value Health. 2011;14:102–9.
   Google Scholar
• Harrison MJ, Davies LM, Bansback NJ, Ingram M, Anis AH, Symmons DP. The validity and responsiveness of generic utility measures in rheumatoid arthritis: a review. J Rheumatol. 2008; 35:592–602.
   PubMed Web of Science ®Google Scholar
• Hoshi D, Inoue E, Igarashi A, Tsutani K, Shidara K, Seto Y, et al. Euro QOL (EQ-5D) based QOL in 5,023 Japanese patients with rheumatoid arthritis in an observational cohort IORRA (abstract). Ann Rheum Dis. 2009;69(Suppl 3):224.
   Google Scholar
• Beresniak A, Gossec L, Goupille P, Saraux A, Bamberger M, Bregman B, et al. Direct cost-modeling of rheumatoid arthritis according to disease activity categories in France. J Rheumatol. 2011;38:439–45.
   PubMed Web of Science ®Google Scholar
• Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum. 2003;48:2750–62.
   PubMed Web of Science ®Google Scholar
• Kobelt G, Lindgren P, Lindroth Y, Jacobson L, Eberhardt K. Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis. Rheumatology (Oxford). 200544: 1169–75.
   Google Scholar
• Kobelt G, Woronoff AS, Richard B, Peeters P, Sany J. Disease status, costs and quality of life of patients with rheumatoid arthritis in France: the ECO-PR Study. Joint Bone Spine. 2008; 75:408–15.
   Google Scholar
• Fries JF. Safety, cost and effectiveness issues with disease modifying anti-rheumatic drugs in rheumatoid arthritis. Ann Rheum Dis. 1999;58:186–9.
   PubMed Web of Science ®Google Scholar
• Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum. 1999;42:1209–18.
   PubMed Web of Science ®Google Scholar
• Strand V, Singh JA. Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. Drugs. 2010;70:121–45.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Han C, van der Heijde DM, Emery P, Bathon JM, Keystone E, Active-Controlled Study of Patients Receiving Inf-liximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group, et al. Radiographic changes in rheuma-toid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrex-ate: the impacts of remission and tumour necrosis factor block-ade. Ann Rheum Dis. 2009;68:823–7.
   Google Scholar
• Han C, Smolen JS, Kavanaugh A, van der Heijde D, Braun J, Westhovens R, et al. The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases. Arthritis Res Ther. 2007;9:R103.
   Google Scholar
• Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al. Comparison of methotrexate monotherapy with a com-bination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372:375–82.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Klareskog L, Singh A, Tornero J, Melo-Gomes J, Codreanu C, et al. Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheu-matoid arthritis: the TEMPO trial. Ann Rheum Dis. 2006;65: 328–34.
   PubMed Web of Science ®Google Scholar
• Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50: 1400–11.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Cifaldi MA, Ray S, Chen N, Weisman MH. Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study. Arthritis Care Res (Hoboken). 2010;62: 226–34.
   Google Scholar
• Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66:1162–7.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Russell AS, Emery P, Abud-Mendoza C, Szechinski J, Westhovens R, et al. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to metho-trexate: 3-year results from the AIM trial. Ann Rheum Dis. 2011; 70:1826–30.
   Google Scholar
• Shourt CA, Crowson CS, Gabriel SE, Matteson EL. Orthopedic surgery among patients with rheumatoid arthritis 1980-2007: a population-based study focused on surgery rates, sex, and mor-tality. J Rheumatol. 2012;39:481–5.
   PubMed Web of Science ®Google Scholar
• Louie GH, Ward MM. Changes in the rates of joint surgery among patients with rheumatoid arthritis in California, 1983-2007. Ann Rheum Dis. 2010;69:868–71.
   PubMed Web of Science ®Google Scholar
• Weiss RJ, Ehlin A, Montgomery SM, Wick MC, Stark A, Wre-tenberg P. Decrease of RA-related orthopaedic surgery of the upper limbs between 1998 and 2004: data from 54,579 Swedish RA inpatients. Rheumatology (Oxford). 2008;47: 491–4.
   Google Scholar
• Weiss RJ, Stark A, Wick MC, Ehlin A, Palmblad K, Wretenberg P. Orthopaedic surgery of the lower limbs in 49,802 rheumatoid arthritis patients: results from the Swedish National Inpatient Registry during 1987 to 2001. Ann Rheum Dis. 2006;65: 335–41.
   PubMed Web of Science ®Google Scholar
• Momohara S, Ikari K, Mochizuki T, Kawamura K, Tsukahara S, Told H, et al. Declining use of synovectomy surgery for patients with rheumatoid arthritis in Japan. Ann Rheum Dis. 2009; 68:291–2.
   PubMed Web of Science ®Google Scholar
• Momohara S, Inoue E, Ikari K, Kawamura K, Tsukahara S, Iwamoto T, et al. Decrease in orthopaedic operations, including total joint replacements, in patients with rheumatoid arthritis between 2001 and 2007: data from Japanese outpatients in a single institute-based large observational cohort (IORRA). Ann Rheum Dis. 2010;69:312–3.
   PubMed Web of Science ®Google Scholar
• Momohara S, Ikari K, Kawakami K, Iwamoto T, Inoue E, Yano K, et al. The increasing disease duration of patients at the time of orthopaedic surgery for rheumatoid arthritis. Rheumatol Int. 2011 [Epub ahead of print].
   Google Scholar
• Kajiyama H, Akama H, Yamanaka H, Shoji A, Matsuda Y, Tanaka E, et al. One third of Japanese patients with rheumatoid arthritis use complementary and alternative medicine. Mod Rheumatol. 2006;16:355–9.
   PubMedGoogle Scholar
• Rat AC, Boissier MC. Rheumatoid arthritis: direct and indirect costs. Joint Bone Spine. 2004;71:518–24.
   PubMed Web of Science ®Google Scholar
• Kobelt G, Jönsson L, Lindgren P, Young A, Eberhardt K. Mod-eling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis. Arthritis Rheum. 2002;46:2310–9.
   PubMed Web of Science ®Google Scholar
• Eberhardt K, Larsson BM, Nived K, Lindqvist E. Work disability in rheumatoid arthritis-development over 15 years and evalua-tion of predictive factors overtime. J Rheumatol. 2007;34:481–7.
   PubMed Web of Science ®Google Scholar
• Filipovic I, Walker D, Forster F, Curry AS. Quantifying the economic burden of productivity loss in rheumatoid arthritis. Rheumatology (Oxford). 2011;50:1083–90.
   PubMed Web of Science ®Google Scholar
• Halpern MT, Cifaldi MA, Kvien TK. Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group. Ann Rheum Dis. 2009;68:930–7.
   Google Scholar
• Bejarano V, Quinn M, Conaghan PG, Reece R, Keenan AM, Walker D, Yorkshire Early Arthritis Register Consortium, et al. Effect of the early use of the anti-tumor necrosis factor ada-limumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum. 2008;59:1467–74.
   Google Scholar
• van Vollenhoven RF, Cifaldi MA, Ray S, Chen N, Weisman MH. Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study. Arthritis Care Res. 2010;62:226–34.
   Google Scholar
• Augustsson J, Neovius M, Cullinane-Carli C, Eksborg S, van Vollenhoven RF. Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry). Ann Rheum Dis. 2010;69:126–31.
   Google Scholar
• Yelin E, Trupin L, Katz P, Lubeck D, Rush S, Wanke L. Asso-ciation between etanercept use and employment outcomes among patients with rheumatoid arthritis. Arthritis Rheum. 2003;48: 3046–54.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Han C, van der Heijde D, Emery P, Bathon JM, Keystone E, et al. Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum. 2006;54:716–22.
   PubMed Web of Science ®Google Scholar
• ter Wee MM, Lems WF, Usan H, Gulpen A, Boonen A. The effect of biological agents on work participation in rheumatoid arthritis patients: a systematic review. Ann Rheum Dis. 2012;71: 161–71.
   Google Scholar
• Kirchhoff T, RuofJ, Mittendorf T, Rihl M, Bernateck M, Mau W, et al. Cost of illness in rheumatoid arthritis in Germany in 1997-98 and 2002: cost drivers and cost savings. Rheumatology (Oxford). 2011;50:756–61.
   PubMed Web of Science ®Google Scholar
• van der Velde G, Pham B, Machado M, Ieraci L, Witteman W, Bombardier C, et al. Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review. Arthritis Care Res (Hoboken). 2011;63:65–78.
   PubMed Web of Science ®Google Scholar
• Doan QV, Chiou CF, Dubois RW. Review of eight pharmaco-economic studies of the value of biologic DMARDs (ada-limumab, etanercept, and infliximab) in the management of rheumatoid arthritis. J Manag Care Pharm. 2006;12:555–69.
   Google Scholar
• Schoels M, Wong J, Scott DL, Zink A, Richards P, Landewé R, et al. Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010;69:995–1003.
   Google Scholar
• Tanno M, Nakamura I, Ito K, Tanaka H, Ohta H, Kobayashi M, et al. Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis. Mod Rheumatol. 2006;16:77–84.
   PubMedGoogle Scholar